Mainz Biomed director awarded 45,000 shares

Tibbitts Gregory J reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 02/19/2026 - 05:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tibbitts Gregory J reported acquisition or exercise transactions in this Form 4 filing.

Mainz Biomed N.V. director Gregory J. Tibbitts reported an equity award of 45,000 Ordinary Shares on February 13, 2026. The shares were granted as restricted stock under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid for the award.

Following this grant, Tibbitts beneficially owned a total of 55,875 Ordinary Shares. In a related footnote, the company notes that 10,875 employee stock options had previously been granted and were reported earlier on a Form 3 filed on January 26, 2026.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Tibbitts Gregory J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	45,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 55,875 shares (Direct)

Holdings Before and After: Ordinary Shares, 10,875 to 55,875 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.
2. F2. 10,875 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mainz Biomed (MYNZ) director Gregory J. Tibbitts report?

Gregory J. Tibbitts reported an award of 45,000 Ordinary Shares. These were granted as restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration required from him for the grant.

At what price were the 45,000 Mainz Biomed (MYNZ) shares granted to Gregory J. Tibbitts?

The 45,000 Ordinary Shares were granted at a price of $0.00 per share. The filing specifies that the grant was a restricted share award under the 2025 Omnibus Incentive Plan, and no cash consideration was paid for receiving these shares.

How many Mainz Biomed (MYNZ) shares does Gregory J. Tibbitts hold after this Form 4 transaction?

After the reported grant, Gregory J. Tibbitts beneficially owns 55,875 Ordinary Shares. This total reflects the addition of 45,000 restricted shares awarded on February 13, 2026, as disclosed in the Form 4 filing for Mainz Biomed N.V.

What equity plan was used for the 45,000-share grant to Mainz Biomed (MYNZ) director Gregory J. Tibbitts?

The 45,000-share award was granted under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan. The filing describes the transaction as a grant of restricted shares pursuant to this plan, with no cash consideration paid by Tibbitts for the shares.

Were any employee stock options mentioned in Gregory J. Tibbitts’ Mainz Biomed (MYNZ) Form 4 filing?

Yes. A footnote states that 10,875 employee stock options were previously granted to Gregory J. Tibbitts. These options were already disclosed in an earlier Form 3 filed on January 26, 2026, and are referenced again for context in this Form 4.

Was cash involved in Gregory J. Tibbitts’ 45,000-share grant from Mainz Biomed (MYNZ)?

No cash changed hands for this grant. The filing explains that the 45,000 Ordinary Shares were a restricted share award under the 2025 Omnibus Incentive Plan, specifically noting that no cash consideration was paid for the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tibbitts Gregory J

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ CA 55129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/13/2026		A		45,000	A	$0(1)	55,875(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.

2. 10,875 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

	/s/ Gregory Tibbits	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.